Top Performing Drug – Ozempic (September Edition)

Shots: PharmaShots’ next episode on the top-performing drug of the month, based on 2021 revenue, focuses on Ozempic, a drug developed and marketed by Novo Nordisk Ozempic (semaglutide) is a human GLP-1 receptor agonist (or GLP-1 analog). It, when taken along with diet and exercise, is proven to improve blood sugar in adults with type 2…

BySenior EditorSeptember 27, 2023

VIEWPOINTS

Ruud Dobber Shares Insights from RWE Data from the REVEAL-CKD Presented at the ERA-EDTA’23

Shots:Ruud talked about the key findings from the new RWE data at ERA-EDTA'23 which demonstrated the staggeringly low rate of diagnosis in chronic kidney disease (CKD)He then discussed the risk factors of CKD and the urgent need to act on the growing global burden of CKD and how this disease is impacting the…

BySenior EditorSeptember 25, 2023

THOUGHTSPOT

Role of Wearables in Cardiovascular Domain

The heart is the muscular organ that pumps blood throughout the body. A group of diseases that affect the heart and blood vessels of the body comes under cardiovascular disease (CVD). Heart disease is globally the major cause of death (~17.3M). Irregular heart functions can lead to heart arrhythmia, heart attack, myocardial infarction, and other…

BySaurabh ChaubeyJuly 12, 2022

Top Performing Drug – Ozempic (September Edition)

Ruud Dobber Shares Insights from RWE Data from the REVEAL-CKD Presented at the ERA-EDTA’23

Role of Wearables in Cardiovascular Domain

Contact US

OUR INFORMATION

FOLLW US

Top Performing Drug – Ozempic (September Edition)

Ruud Dobber Shares Insights from RWE Data from the REVEAL-CKD Presented at the ERA-EDTA’23

Role of Wearables in Cardiovascular Domain

FOLLW US

Sign Up to Our Newsletter